XORTX Therapeutics Inc. filed a 6-K report on April 2, 2024, which includes consolidated financial statements and management analysis for the years 2021 to 2023. The filing is categorized as 'Quarterly Earnings Reports' and is considered significant, reflecting the company's ongoing financial obligations and regulatory compliance.